We invest in what comes next

A food-tech company exploring fungal-based space food from a new facility at NASA Kennedy Space Center. For Earth-side applications, the ability to produce food with minimum resources can be of enormous help in disaster relief when there’s no supply chain to kickstart food production.

A leading Biotech company catalysing the DNA-Economy by enabling the development of disruptive biotechnologies with precision fermentation, from lab-scale experiments to large-scale pilot runs. Synbio Powerlabs secured € 6.6 million funding for a unique biotechnology pilot plant for precision fermentation.

Clingate is playing a pivotal role in Finland's biotechnology landscape. It is managing large industrial equipment to catalyze advancements in biotechnology.Clingate is the solution to empower researchers, laboratories, and industries to propel real breakthroughs in the field..

Synbio Powerhouse builds connections between researchers, businesses, and investors to promote and develop Synthetic Biology in the world. As members of their ecosystem, individuals will access valuable services and receive in-depth insight into the latest trends and developments in synthetic biology.

The secrets of aromas revealed. Nordiquan is pioneering breakthrough technologies with AI and synthetic biology. The mission is to reinvent the most desired flavours by harnessing the nature of their essence with science and technology.

Immensa Biotech is positioned at the forefront of disruption in the biotechnology sector, it specializes in pioneering new models that redefine traditional development and innovation approaches. Immensa leads in large-scale precision fermentation projects and novel food production methods. Embracing the frontiers of a new era, it thrives on all the possibilities unlocked by scientific breakthroughs and emerging technologies. As a key biotechnology and biosciences presence in the Nordics, Immensa Biotech is a driving force behind transformative changes in the global biotechnology scene.

The next generation of pharmaceuticals aims to treat patients with neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules. In November 2022, the biotech company announced FDA Investigational New Drug clearance for its New Chemical Entity Triptax™ targeting Treatment-Resistant Depression. A Phase II Clinical Trial for its 5-MeO-DMT based BMND08 candidate for depression and anxiety in Alzheimer’s Disease is commencing in Q2 2023.

Industry-leading, vertically integrated hemp business that produces high-quality health supplements derived from phytocannabinoid extracts.